Pfizer Focusing Obesity Rx Development Efforts On Combination Therapies
This article was originally published in The Pink Sheet Daily
Executive Summary
The company's antihypertensive/cholesterol-lowering agent Caduet and the atorvastatin/torcetrapib combination have potential for use in metabolic syndrome, Pfizer VP-Cardiovascular Medical Group Palmer says. Future obesity therapies will require comparable efficacy to Abbott's Meridia but with a more tolerable safety profile, he says.